Actively Recruiting
Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD
Led by Northern Jiangsu People's Hospital · Updated on 2026-03-31
20
Participants Needed
1
Research Sites
78 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy and azygoportal disconnection.
CONDITIONS
Official Title
Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- A clinical, radiological, or histologic diagnosis of cirrhosis of any cause
- History of portal hypertension bleeding
- Enlarged spleen with secondary hypersplenism
- No portal vein thrombosis detected by ultrasound and angio-CT before surgery
- Underwent laparoscopic splenectomy at the study center
- Took 2.5 mg Apixaban twice daily or 100 mg aspirin once daily for 6 months starting from post-operative day 3
- Received low molecular weight heparin injections for 5 days starting from post-operative day 3
- Took oral dipyridamole 25 mg three times daily for 3 months starting from post-operative day 3
- No imaging evidence of portal vein thrombosis between 6 to 12 months after surgery
- Developed portal vein thrombosis more than 12 months after surgery
- Provided informed consent to participate in the study
You will not qualify if you...
- Having hepatocellular carcinoma or any other cancer
- Having a hypercoagulable state not related to liver disease
- Using oral contraceptives, anticoagulants, or anti-platelet drugs
- Classified as Child-Pugh C liver disease
- Recent peptic ulcer disease
- History of hemorrhagic stroke
- Being pregnant
- Having uncontrolled high blood pressure
- Infection with HIV
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Clinical Medical College
Yangzhou, Jiangsu, China, 225001
Actively Recruiting
Research Team
G
Guo-Qing Jiang, MD
CONTACT
D
Dou-Sheng Bai, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here